133 related articles for article (PubMed ID: 12962362)
1. Post-exposure effects of cefepime and cefpirome on isogenic Escherichia coli hosts producing SHV-extended-spectrum beta-lactamases.
Bedenic B; Vranes J
J Chemother; 2003 Aug; 15(4):342-9. PubMed ID: 12962362
[TBL] [Abstract][Full Text] [Related]
2. Effect of inoculum size on the antibacterial activity of cefpirome and cefepime against Klebsiella pneumoniae strains producing SHV extended-spectrum beta-lactamases.
Bedenić B; Beader N; Zagar Z
Clin Microbiol Infect; 2001 Nov; 7(11):626-35. PubMed ID: 11737087
[TBL] [Abstract][Full Text] [Related]
3. Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula.
Maglio D; Ong C; Banevicius MA; Geng Q; Nightingale CH; Nicolau DP
Antimicrob Agents Chemother; 2004 Jun; 48(6):1941-7. PubMed ID: 15155182
[TBL] [Abstract][Full Text] [Related]
4. Bactericidal activity of oral beta-lactam antibiotics in plasma and urine versus isogenic Escherichia coli strains producing broad- and extended-spectrum beta-lactamases.
Bedenic B; Vranes J; Suto S; Zagar Z
Int J Antimicrob Agents; 2005 Jun; 25(6):479-87. PubMed ID: 15894465
[TBL] [Abstract][Full Text] [Related]
5. SHV-type extended-spectrum beta-lactamase production is associated with Reduced cefepime susceptibility in Enterobacter cloacae.
Szabó D; Bonomo RA; Silveira F; Pasculle AW; Baxter C; Linden PK; Hujer AM; Hujer KM; Deeley K; Paterson DL
J Clin Microbiol; 2005 Oct; 43(10):5058-64. PubMed ID: 16207962
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of extended spectrum beta-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness.
Kotapati S; Kuti JL; Nightingale CH; Nicolau DP
J Infect; 2005 Oct; 51(3):211-7. PubMed ID: 16230218
[TBL] [Abstract][Full Text] [Related]
7. Effects of phenotype and genotype on methods for detection of extended-spectrum-beta-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway.
Tofteland S; Haldorsen B; Dahl KH; Simonsen GS; Steinbakk M; Walsh TR; Sundsfjord A;
J Clin Microbiol; 2007 Jan; 45(1):199-205. PubMed ID: 17079502
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases.
Calbo E; Romaní V; Xercavins M; Gómez L; Vidal CG; Quintana S; Vila J; Garau J
J Antimicrob Chemother; 2006 Apr; 57(4):780-3. PubMed ID: 16492721
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic and genotypic detection of ESBL mediated cephalosporin resistance in Klebsiella pneumoniae: emergence of high resistance against cefepime, the fourth generation cephalosporin.
Grover SS; Sharma M; Chattopadhya D; Kapoor H; Pasha ST; Singh G
J Infect; 2006 Oct; 53(4):279-88. PubMed ID: 16488476
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of temocillin against extended spectrum beta-lactamase-producing Escherichia coli.
Rodriguez-Villalobos H; Malaviolle V; Frankard J; de Mendonça R; Nonhoff C; Struelens MJ
J Antimicrob Chemother; 2006 Apr; 57(4):771-4. PubMed ID: 16501056
[TBL] [Abstract][Full Text] [Related]
11. [Extended-spectrum beta-lactamase in Klebsiella pneumoniae and Escherichia coli isolates].
Xiong Z; Zhu D; Zhang Y; Wang F
Zhonghua Yi Xue Za Zhi; 2002 Nov; 82(21):1476-9. PubMed ID: 12509910
[TBL] [Abstract][Full Text] [Related]
12. Characterization of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli obtained from Danish pigs, pig farmers and their families from farms with high or no consumption of third- or fourth-generation cephalosporins.
Hammerum AM; Larsen J; Andersen VD; Lester CH; Skovgaard Skytte TS; Hansen F; Olsen SS; Mordhorst H; Skov RL; Aarestrup FM; Agersø Y
J Antimicrob Chemother; 2014 Oct; 69(10):2650-7. PubMed ID: 24908045
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of parenteral beta-lactam antimicrobials against TEM-10-, TEM-26- and SHV-5-derived extended-spectrum beta-lactamases expressed in an isogenic Escherichia coli host.
Rebuck JA; Olsen KM; Fey PD; Bergman KL; Rupp ME
J Antimicrob Chemother; 2000 Sep; 46(3):461-4. PubMed ID: 10980175
[TBL] [Abstract][Full Text] [Related]
14. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007.
Jean SS; Lee WS; Bai KJ; Lam C; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
J Microbiol Immunol Infect; 2015 Feb; 48(1):85-91. PubMed ID: 23973410
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility patterns to extended-spectrum cephalosporins among Enterobacteriaceae harbouring extended-spectrum β-lactamases using the updated Clinical and Laboratory Standards Institute interpretive criteria.
Kristo I; Pitiriga V; Poulou A; Zarkotou O; Kimouli M; Pournaras S; Tsakris A
Int J Antimicrob Agents; 2013 Apr; 41(4):383-7. PubMed ID: 23375981
[TBL] [Abstract][Full Text] [Related]
16. Extended spectrum beta-lactamases in Escherichia coli & Klebsiella pneumoniae & associated risk factors.
Goyal A; Prasad KN; Prasad A; Gupta S; Ghoshal U; Ayyagari A
Indian J Med Res; 2009 Jun; 129(6):695-700. PubMed ID: 19692752
[TBL] [Abstract][Full Text] [Related]
17. Control of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a children's hospital by changing antimicrobial agent usage policy.
Lee J; Pai H; Kim YK; Kim NH; Eun BW; Kang HJ; Park KH; Choi EH; Shin HY; Kim EC; Lee HJ; Ahn HS
J Antimicrob Chemother; 2007 Sep; 60(3):629-37. PubMed ID: 17599919
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of MicroScan WalkAway and Vitek 2 for determination of the susceptibility of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates to cefepime, cefotaxime and ceftazidime.
Jang W; Park YJ; Park KG; Yu J
J Antimicrob Chemother; 2013 Oct; 68(10):2282-5. PubMed ID: 23671215
[TBL] [Abstract][Full Text] [Related]
19. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Thomson KS; Moland ES
Antimicrob Agents Chemother; 2001 Dec; 45(12):3548-54. PubMed ID: 11709338
[TBL] [Abstract][Full Text] [Related]
20. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
